Abstract Library

#4437 Pancreatic metastases in neuroendocrine neoplasia: A systematic review

Introduction: Neuroendocrine neoplasias (NENs) are a heterogeneous group of neoplasms that often metastasise to distant organs, with the liver and bones as common targets. However, metastases to the pancreas are uncommon, accounting for 2–5% of pancreatic malignancies.

Conference:

Presenting Author:

Authors: Rinzivillo M, Romano E, Dell' Unto E, Marasco M, Panzuto F,

Keywords: pancreatic metastasis, 68Gallium-PET, incidence,

#4389 The LOLA trial: Phase II trial with combination of cabozantinib plus lanreotide in gastroenteropancreatic (GEP) and thoracic neuroendocrine tumours (NETs) – Interim results of step 1

Introduction: LOLA is an Italian, multicentre, open-label, double cohort, non-randomised, 3-stage, phase 2 trial aiming to assess the safety and activity of the combination of cabozantinib (CABO) + lanreotide (LAN) in patients (pts) with advanced or metastatic GEP and unknown primary NETs with Ki-67 > 10% or thoracic NET. In NETs sunitinib is the only TKI approved in advanced pancreatic NETs. While CABO has been reported superior to sunitinib in renal cancer its role in NETs is still investigational.

Conference:

Presenting Author: Oldani S

Authors: Oldani S, Morano F, Brizzi M, Giuffrida D, Panzuto F,

Keywords: gastroenteropancreatic neuroendocrine tumour, cabozantinib, lanreotide, clinical trial,

#4322 Clinical outcomes of patients with rectal neuroendocrine tumours smaller than 10mm after endoscopic resection

Introduction: Rectal neuroendocrine tumours (r-NETs) generally have a good prognosis, but up to 20% may be misdiagnosed during endoscopy, risking inadequate treatment. Prognosis factors include tumour size, grading, staging, and lymphovascular invasion, with guidelines recommending endoscopic resection for small, low-grade lesions.

Conference:

Presenting Author:

Authors: Dell' Unto E, Riding G, Rimondi A, Panzuto F, Luong T,

Keywords: Rectal Carcinoid, Rectal Neuroendocrine Tumour, Endoscopic Resection,

#4145 Itanet national prospective database: A comprehensive analysis of epidemiology and clinical presentation of GEP-NEN in Italy

Introduction: Epidemiological data on GEP-NEN are heterogeneous, making interpretation difficult.

Conference:

Presenting Author:

Authors: Panzuto F, Partelli S, Campana D, Pusceddu S, Spada F,

Keywords: Neuroendocrine tumor, epidemiology, registry, management, database,

#3135 Endoscopic resection of type I gastric neuroendocrine neoplasia (NEN): A systematic review

Introduction: Although relatively uncommon, the incidence of type I gastric NEN has been rising over time. Since they are considered indolent neoplasms, with a low metastatic potential, endoscopic resection is the treatment of choice. However, correct endoscopic management is not well established.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Magi L, Esposito G, Rinzivillo M, Annibale B, Panzuto F,

Keywords: gastric carcinoid, gastric neuroendocrine neoplasia, gastric neuroendocrine tumor, endoscopic resection, mucosal resection, submucosal dissection, polipectomy,